Phage Therapy Market Overview

Posted 2026-06-18 07:15:40

The Phage Therapy Market is emerging as a critical solution to the global antibiotic resistance crisis. Valued at USD 1,100 million in 2024, this market is projected to reach USD 3,000 million by 2035, growing at a robust CAGR of 9.5%. Bacteriophages are viruses that specifically target and destroy bacteria, offering a precise alternative when traditional antibiotics fail.

The market segments by phage type into lytic phages, lysogenic phages, single-phage preparations, and phage cocktails. Lytic phages currently lead due to their direct bacterial killing mechanism. Applications span bacterial infections, antibiotic resistance cases, biofilm infections, and inflammatory diseases, with bacterial infections holding the largest share at approximately 40%.

North America dominates the regional landscape with a 40% market share, supported by advanced healthcare infrastructure and favorable regulatory frameworks. Europe and Asia-Pacific follow closely, with APAC showing the highest growth potential. Key players include Adaptive Phage Therapeutics, Intralytix, and Phagelux.

FAQ

Q1: What is the current size of the phage therapy market? A: The market was valued at USD 1,100 million in 2024.

Q2: What is driving phage therapy market growth? A: Rising antibiotic resistance and increasing prevalence of multidrug-resistant infections are primary drivers.

Q3: Which region leads the phage therapy market? A: North America holds approximately 40% of the global market share.